Viel Christian, Brandtner Adrian T, Weißhaar Alexander, Lehto Alina, Fuchs Marius, Klein Jochen
Institute of Pharmacology and Clinical Pharmacy, College of Pharmacy, Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany.
Institute of Physiology I, Rheinische Friedrich-Wilhelms-Universität, Sigmund-Freud-Straße 25, Venusberg-Campus 1, 53105 Bonn, Germany.
Pharmaceuticals (Basel). 2021 Nov 24;14(12):1218. doi: 10.3390/ph14121218.
Glucose hypometabolism, mitochondrial dysfunction, and cholinergic deficits have been reported in early stages of Alzheimer's disease (AD). Here, we examine these parameters in TgF344-AD rats, an Alzheimer model that carries amyloid precursor protein and presenilin-1 mutations, and of wild type F344 rats. In mitochondria isolated from rat hippocampi, we found reductions of complex I and oxidative phosphorylation in transgenic rats. Further impairments, also of complex II, were observed in aged (wild-type and transgenic) rats. Treatment with a "cocktail" containing magnesium orotate, benfotiamine, folic acid, cyanocobalamin, and cholecalciferol did not affect mitochondrial activities in wild-type rats but restored diminished activities in transgenic rats to wild-type levels. Glucose, lactate, and pyruvate levels were unchanged by age, genetic background, or treatment. Using microdialysis, we also investigated extracellular concentrations of acetylcholine that were strongly reduced in transgenic animals. Again, ACh levels in wild-type rats did not change upon treatment with nutrients, whereas the cocktail increased hippocampal acetylcholine levels under physiological stimulation. We conclude that TgF344-AD rats display a distinct mitochondrial and cholinergic dysfunction not unlike the findings in patients suffering from AD. This dysfunction can be partially corrected by the application of the "cocktail" which is particularly active in aged rats. We suggest that the TgF344-AD rat is a promising model to further investigate mitochondrial and cholinergic dysfunction and potential treatment approaches for AD.
在阿尔茨海默病(AD)早期已报道存在葡萄糖代谢减退、线粒体功能障碍和胆碱能缺陷。在此,我们在携带淀粉样前体蛋白和早老素 -1 突变的阿尔茨海默病模型 TgF344 - AD 大鼠以及野生型 F344 大鼠中检测这些参数。在从大鼠海马体分离出的线粒体中,我们发现转基因大鼠中复合物 I 和氧化磷酸化水平降低。在老年(野生型和转基因)大鼠中还观察到复合物 II 也有进一步损伤。用含有乳清酸镁、苯磷硫胺、叶酸、氰钴胺和胆钙化醇的“鸡尾酒”疗法处理,对野生型大鼠的线粒体活性没有影响,但能将转基因大鼠中降低的活性恢复到野生型水平。葡萄糖、乳酸和丙酮酸水平不受年龄、遗传背景或治疗的影响。使用微透析技术,我们还研究了细胞外乙酰胆碱浓度,其在转基因动物中显著降低。同样,营养物质处理后野生型大鼠的乙酰胆碱水平没有变化,而这种“鸡尾酒”疗法在生理刺激下可提高海马体乙酰胆碱水平。我们得出结论,TgF344 - AD 大鼠表现出与 AD 患者相似的明显线粒体和胆碱能功能障碍。这种功能障碍可通过应用在老年大鼠中特别有效的“鸡尾酒”疗法得到部分纠正。我们认为 TgF344 - AD 大鼠是进一步研究线粒体和胆碱能功能障碍以及 AD 潜在治疗方法的有前景的模型。